Replies to post #129862 on Biotech Values

[NP1986]

However, isn't best supportive care usually reserved for patients with no other approved treatment options? That would place this trial in a last-ditch population. That would also be consistent with the description provided at your link: patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC.

Ah, I skipped over the part where it said "who have progressed on/after all approved drugs for CRC". Yes, BSC is usually reserved for when there are no other treatment options, which was why the inclusion criteria on clinicaltrials.gov surprised me. It makes more sense now.

So SNY/REGN don't have anything to worry about in this case, but regorafenib will compete with perifosine (if the latter manages to meet its primary endpoint).